Results 31 to 40 of about 8,230 (180)

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5‐Year Analysis of the Phase 3 POETYK PSO‐1, PSO‐4, and Long‐Term Extension Trials

The Journal of Dermatology, EarlyView.
ABSTRACT Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of moderate to severe plaque psoriasis, as well as generalized pustular and erythrodermic psoriasis in Japan. Deucravacitinib 6 mg once daily was efficacious and well tolerated through 3 years in the pooled population of ...
Yukari Okubo, Akimichi Morita, Yayoi Tada, Shinichi Imafuku, April W. Armstrong, Andrew Blauvelt, John Vaile, Zoran Popmihajlov, Janice Li, Rajesh Sawant, Katsuyoshi Habiro, Katsuki Tsuritani, Mamitaro Ohtsuki   +12 more
wiley   +1 more source

A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial

Trials, 2018
Background Palmoplantar pustulosis is a rare but painful and debilitating disease. It consistently ranks the highest of all psoriasis phenotypic variants in terms of symptoms and functional impairment.
Victoria Cornelius, Rosemary Wilson, Suzie Cro, Jonathan Barker, David Burden, Christopher E. M. Griffiths, Helen Lachmann, Helen McAteer, Nick Reynolds, Andrew Pink, Richard B. Warren, Francesca Capon, Catherine Smith   +12 more
doaj   +1 more source

Generalized Pustular Psoriasis Flare-Up after Both Doses of BBIBP-CorV Vaccination in a Patient under Adalimumab Treatment: A Case Report

Case Reports in Dermatology, 2023
Generalized pustular psoriasis is a possibly serious condition that can be triggered by various factors. Previous studies show a slight likelihood of disease exacerbation subsequent to COVID-19 vaccination.
Dorsa Dayani, Hatam Rokhafrouz, Kamran Balighi   +2 more
doaj   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada, Yoshiko Maeda, Miyuki Hasegawa, Motonobu Sakaguchi, Takamasa Hashimoto, Teruko Narusawa, Nobuyoshi Takabayashi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda   +9 more
wiley   +1 more source

Generalized pustular psoriasis successfully treated with spesolimab: A case report

SAGE Open Medical Case Reports
Generalized pustular psoriasis is defined as a primary, sterile, macroscopically visible pustular eruption on non-acral skin, which can occur with or without systemic inflammation and/or psoriasis vulgaris, and can either be relapsing or be persistent ...
Noemi Brigenti, Paolo Gisondi, Francesco Bellinato, Giampiero Girolomoni   +3 more
doaj   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

PeakPASI as a marker of maximum psoriasis severity: a single‐center, cross‐sectional retrospective and questionnaire‐based study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background The Psoriasis Area and Severity Index (PASI) is the standard measure for psoriasis severity but reflects only a single time point and may underestimate long‐term disease burden. To assess whether the highest‐ever recorded PASI (PeakPASI) can serve as a marker of historical disease severity and correlate with treatment burden and ...
Simran Wilkhoo, Stefanie Ziehfreund, Enya Müller, Hanna Wecker, Stefanie Eyerich, Tilo Biedermann, Alexander Zink   +6 more
wiley   +1 more source

Pustular and Erythrodermic Psoriasis

Dermatologic Clinics, 1995
Pustular psoriasis and erythrodermic psoriasis are generally less stable, more challenging to treat, and more severe for the patient than classical plaque-type psoriasis vulgaris. The risk for systemic infection and overwhelming sepsis in these forms of psoriasis emphasizes the potential life-threatening impact of psoriasis.
J H, Prystowsky, P R, Cohen
openaire   +2 more sources

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Pustular psoriasis of pregnancy (Impetigo herpetiformis) - case report [PDF]

Anais Brasileiros de Dermatologia, 2013
Impetigo herpetiformis is a rare dermatosis of pregnancy with typical onset during the last trimester of pregnancy and rapid resolution in the postpartum period. Clinically and histologically, it is consistent with pustular psoriasis. This similarity has
Rogerio Nabor Kondo, Fernanda Mendes Araújo, Allamanda Moura Pereira, Vivian Cristina Holanda Lopes, Ligia Márcia Mario Martins   +4 more
doaj   +1 more source